ANTIUROLITHIC | RM Potassium Citrate | RiteMED

RM Potassium Citrate


Each tablet contains:

Potassium Citrate sachet


P 14.88

Price Comparison

14.88 -

Product Details

What is this medicine used for?

For the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.


How much and how often should you use this medicine?

Inpatients with severe hypocitraturia (urinary citrate of less than 150 mg/day), therapy should be initiated at a dosage of 60 mEq/day (20 mEq three times/day or 15 mEq four times/day with meals or within 30 minutes after meals or bedtime snack. In patients with mild•moderate hypocitraturia (>150 mg/day). Potassium Citrate tablet should be initiated at a dosage of 30 mEq/ day (10 mEq three times/day with meals). Twenty-four hour urinary citrate and/or urinary pH measurements should be used to determine the adequacy of the initial dosage and to evaluate the effectiveness of any dosage change. In addition, urinary citrate and/or pH should be measured every four months. Or as prescribed by the physician.



Potassium Citrate tablet is contraindicated in patients with hyperkalemia (or who have conditions predisposing them to hyperkalemia), as a further the in serum potassium concentration may produce cardiac arrest, Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown, or the administration of potassium•sparing agent (such as triamterene, spironolactone or amiloride). Potassium Citrate tablet is contraindicated in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as dose suffering from delayed gastric emptying, esophageal compression, intestinal


Warning and Precautions

Hyperkalemia: In patients with impaired mechanisms for excreting potassium. Potassium Citrate tablet administration can produce hyperkalemia and cardiac arrest. Potentially fatal hyperkalemia can develop rapidly and can be asymptomatic. The use of Potassium Citrate tablet in patients with chronic renal failure, or any other condition which impairs potassium excretion such as severe myocardial damage or heart failure, should be avoided. Interaction with potassium•sparing diuretics: Concomitant administration of Potassium Citrate tablet and a potassium-sparing diuretic (such as triamterene, spironolactone or amiloride) should be avoided, since the simultaneous administration of these agents can produce severe hyperkalemia. If there is severe vomiting, abdominal pain or gastrointestinal bleeding, Potassium Citrate tablet should be discontinued immediately and the possibility of bowel perforation or obstruction investigated. Precautions: Physicians should consider reminding the patient of the following: To take each dose without crushing, chewing or sucking the tablet and to take this medicine only as directed. This is especially important if the patient is also taking both diuretics and digitalis preparations; to check with physician if there is trouble swallowing tablets or if the tablet seems to stick in the throat; to check with the doctor at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.


Available in all leading drugstores nationwide